Bactiguard enters new partnership for Italy

Bactiguard has entered partnership with Gada Italia Srl (“Gada”), a specialized and leading distributor of medical devices and integrated healthcare services. 

“The Gada group is a leading provider of integrated healthcare solutions to the public and private hospitals in Italy and we are confident that they have the competence and resources required to offer advanced infection prevention solutions and strengthen the Bactiguard brand in Italy”, says Christian Kinch, CEO.

“We have not been satisfied with the sales development in Italy for some time and have therefore been searching for a new distributor. Expanding our coverage, together with an experienced and well connected partner is an important milestone”, Christian Kinch continues.

Since 2016, Bactiguard has increased its European footprint significantly, by adding Austria, Germany, Poland and Switzerland. Italy is one of the largest European countries, with a population of close to 61 million and more than 1,100 hospitals, with 370 intensive care units (ICU).

“Gada has a strong focus on innovative technologies and dedicated commitment in Cardiovascular and Blood management working close to Intensive care units.  Hospital acquired infections are frequent in Italy and there is a shortage of beds. In the ICUs, infection rates are significantly higher and patients are more exposed, which increases the need for prevention. Bactiguard’s innovative solution for infection prevention saves lives, protects vulnerable patients and shortens their hospital stay. We are therefore very enthusiastic about this new partnership,” says Davide Ciattoni CEO of the Gada Group.

Gada is a specialized and leading distributor of medical devices and integrated healthcare services to the public and private healthcare sector. It has evolved from a group of successful regional distribution companies and is among the top 5 medical device companies in Italy, with a turnover of 70 m EUR. 

For further information, please contact:

Cecilia Edström, SVP Sales and New Business, mobile: +46 722 262 328

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com


About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com